NIH Grand Rounds Interactive TV Series Will Premiere Next Year

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 10
Volume 5
Issue 10

BETHESDA, Md--A clinical education television series--Bench to Bedside--NIH Grand Rounds--is set to debut on January 15, 1997. Once a month, the world's leading clinicians from the various NIH institutes will discuss critical medical topics of the day.

BETHESDA, Md--A clinical education television series--Bench toBedside--NIH Grand Rounds--is set to debut on January 15, 1997.Once a month, the world's leading clinicians from the variousNIH institutes will discuss critical medical topics of the day.

The interactive program, sponsored by the NIH and CenterNet, thetelevision network of the Association of Academic Health Centers,will offer category 1 CME credit and will be made available toinstitutions outside of academic centers, including VA and communityhospitals.

For CenterNet subscription information, write: CenterNet, c/oHMTV, 1800 Diagonal Road, Suite 600, Alexandria, VA 22314 or callTom Shaw at 703-684-4415. The network can provide technical assistancefor institutions wishing to receive CenterNet programming.

Articles in this issue
Anesthetic Interventions Rise When Anesthesiologists Join the Pain Team
Worldwide UN Survey Shows Many Impediments to Morphine Availability
Case-Based Pain Curriculum Used in Canadian Schools
Effective Physician and Patient Communication Is Essential in Palliative Care
Withdrawal Syndrome After Stopping Opioids Is Not Evidence of Drug Dependence, WHO Committee Says
Brief Pain Inventory and Faces Scale Perform Well in a Group of Low-Income, Primarily Black Cancer Patients
Whole-Body Vibration Within Specified Frequency Range May Provide Pain Relief
Pain Descriptions May Predict Presence of Neuropathic Pain
Neurotoxicity Related to High-Dose Opioid Therapy Can Be Managed
Epidural Morphine Relieves Pain in Advanced Cancer, But May Not Influence Quality of Life
Dr. Payne Urges Strategies to Overcome Barriers to Use of Cancer Pain Guidelines
Program Trains Community Opinion Leaders in Principles of Pain Control
Postmarketing Surveillance for Drug Abuse Supports Nonscheduled Status of Tramadol
Consider Quality of Life and Patient Preference When Choosing Pain Relief
Patients' Pain Anxiety Levels Vary Depending on the Type of Pain, the Patient's Gender, and Pain Duration

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
2 experts in this video
2 experts in this video
Considering which non–muscle-invasive bladder cancer cases may be cured by surgery alone may help mitigate overtreatment in this patient group.
Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
Related Content
JNJ’4496 Demonstrates Clinical Benefit, Safety in Relapsed/Refractory LBCL

JNJ’4496 Demonstrates Clinical Benefit, Safety in Relapsed/Refractory LBCL

Tim Cortese
June 13th 2025
Article

JNJ’4496 at 75 M CAR T cells elicited an ORR of 100% in patients with relapsed or refractory large B-cell lymphoma who received 1 prior line of treatment.

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

Data from APPULSE-PNH may support oral iptacopan as a potentially practice-changing option in patients with paroxysmal nocturnal hemoglobinuria.

Iptacopan Yields Meaningful Hemoglobin Improvements in Pretreated PNH Group

Russ Conroy
June 13th 2025
Article

Data from APPULSE-PNH may support oral iptacopan as a potentially practice-changing option in patients with paroxysmal nocturnal hemoglobinuria.

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
June 5th 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging

Results from the phase 3 POD1UM-303/InterAACT-2 trial demonstrated improved PFS and OS in patients with locally recurrent or metastatic SCAC.

Adding Retifanlimab to Chemo Yields Clinical Benefit in Inoperable SCAC

Tim Cortese
June 13th 2025
Article

Results from the phase 3 POD1UM-303/InterAACT-2 trial demonstrated improved PFS and OS in patients with locally recurrent or metastatic SCAC.

The FDA decision follows phase 2 CANFOUR trial data showing a 2-year survival rate of 35% in IL1RAP-high metastatic pancreatic ductal adenocarcinoma.

Nadunolimab Earns FDA Fast-Track Designation in Metastatic PDAC

Roman Fabbricatore
June 13th 2025
Article

The FDA decision follows phase 2 CANFOUR trial data showing a 2-year survival rate of 35% in IL1RAP-high metastatic pancreatic ductal adenocarcinoma.